Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million
More:
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in a fireside chat at the upcoming Cowen 4th Annual IO Next Summit on Friday, November 13, 2020 at 10:45 a.m. ET. The discussion will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27).
Visit link:
Surface Oncology to Present at the Cowen IO Next Summit
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update.
Read more:
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:
Continued here:
MacroGenics to Participate in Upcoming Investor Conferences
- Firdapse® Third Quarter Net Revenues of $29.2 Million
See the original post:
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
Company delivers strong results despite being adversely affected by California Wildfires
See the rest here:
Indus Holdings, Inc. Reports Record Third Quarter 2020 Results
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease (PD).
Read more from the original source:
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
Board Member Brian Shure will join executive team as Chief Financial OfficerSteve Neil will remain at the Company in a senior capacity
Read the rest here:
Indus Holdings, Inc. Announces New Chief Financial Officer
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).
Excerpt from:
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
The cell and gene therapy CDMO will build additional facilities at its German and Japanese locations.
The contract development and manufacturing organization (CDMO) specializing in cell and gene therapies announced two separate investments of $40.7 million (34.2 million) into its Ottobrunn, Germany, site, and $23.8 million for its Yokohama, Japan, site.
Both regions now come under the umbrella of Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, after a rebrand in September to unify the name of its three businesses located in North America (previously, Hitachi Chemical Advanced Therapeutics Solutions (HCATS)), Europe (apceth Biopharma), and Japan (Hitachi Chemical).
Image: iStock/oatawa
The Japanese company acquired apceth last year for $86 million and will now add a 6,650-square-meter facility to the German site. The space will include additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space.
Once operational in 2023, the facility will more than triple the current clean room capacity.
A spokesperson for Minaris explained that the facility will feature a modular design, which allows the company to combine two smaller units into one large ball room and to shift from a grade B to grade C to grade B environment according to our clients needs.
The European site became one of the first CDMOs to manufacture a commercial gene therapy, after agreeing a deal with bluebird bio to manufacture its Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) product last year.
While the companys Japanese site will also receive an additional facility, which will cover 4,000-square-meters and is scheduled to start operations in October 2022.
The space will be used specifically for the commercial manufacture of regenerative medicine, particularly cancer immunotherapies and somatic stem cells, doubling the sites existing capacity.
Minaris global presence for a cell and gene specialist is unusual for an industry often concentrated in the US. However, the spokesperson for Minaris outlined that a global position confers an advantage to our clients that are seeking a global manufacturer to produce their product in different regions for example, clients with autologous cell products that need a manufacturing site close to the patients.
Additionally, We have regulatory expertise in Europe, Japan and the US and can leverage the expertise of one region to another, the spokesperson added.
Read the rest here:
Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider